Target intelligence / Profile preview

Arabinosyltransferase (EmbA, EmbB, and EmbC) (Emb)

Target
Emb
Molecular classification
Enzyme, Glycosyltransferase, Membrane protein
01

Overview

Arabinosyltransferases are essential enzymes in Mycobacterium tuberculosis that catalyze the polymerization of D-arabinofuranose into the arabinan domains of the mycobacterial cell wall. This enzyme family, comprising EmbA, EmbB, and EmbC, utilizes decaprenyl-phospho-arabinose as a sugar donor to build the arabinogalactan and lipoarabinomannan layers (Zhang et al., 2020, Science). Arabinogalactan is a core structural component that tethers the peptidoglycan to the outer mycolic acid layer, while lipoarabinomannan plays a significant role in modulating the host immune response during infection (Goude et al., 2009, Journal of Bacteriology). Because these enzymes are vital for maintaining the integrity of the mycobacterial cell envelope, they are critical targets for antimicrobial intervention. The first-line antitubercular drug ethambutol exerts its bactericidal effect by inhibiting these arabinosyltransferases, specifically targeting the EmbB and EmbA subunits (Telenti et al., 1997, Nature Medicine). Disruption of this pathway leads to increased cell wall permeability and eventual bacterial death. Resistance to ethambutol is frequently associated with specific mutations in the embB gene, highlighting the enzyme's importance in clinical outcomes (Safi et al., 2013, Nature Communications).

Other names
EmbAEmbBEmbCArabinosyltransferase AArabinosyltransferase BArabinosyltransferase CMycobacterium tuberculosis arabinosyltransferase complexEmbCAB complex
02

Mechanism of action

Inhibition of the transfer of arabinose units from the donor decaprenyl-phospho-arabinose to the cell wall acceptor, disrupting the assembly of the arabinogalactan and lipoarabinomannan layers.

03

Biological functions

Cell wall biosynthesisArabinogalactan synthesisLipoarabinomannan synthesisPolymerization of D-arabinofuranoseMaintenance of cell envelope integrity
04

Disease associations

TuberculosisMycobacterium tuberculosis infection
05

Safety considerations

Optic neuritis (ethambutol-induced)Drug resistance (mutations in embCAB operon)Poor penetration into certain necrotic lesionsPotential for hepatotoxicity when used in combination therapy
06

Interacting drugs

Ethambutol

1 more in the full profile.

07

Biomarkers

embB gene mutations (e.g., Met306 substitution)Sputum culture conversionChest X-ray improvementMolecular detection of embCAB operon polymorphisms

Beyond the preview

Go deeper on Arabinosyltransferase (EmbA, EmbB, and EmbC) (Emb).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Arabinosyltransferase (EmbA, EmbB, and EmbC) (Emb).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call